Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study
| 详细信息 | 推荐本文 | |
- 作者：Yoichi Arai ; Hideyuki Akaza ; Takashi Deguchi ; Masato Fujisawa ; Mikio Hayashi ; Yoshihiko Hirao ; Hiroshi Kanetake ; Seiji Naito ; Mikio Namiki and Masaaki Tachibana ; et al.
- 关键词：Advanced prostate cancer ; Bicalutamide ; Luteinizing hormone releasing hormone agonist ; Maximum androgen blockade ; Quality of life
- 刊名：Journal of Cancer Research and Clinical Oncology
- 出版时间：December, 2008
- 出版年：2008
- 期刊代码：116_0171-5216
- 类别：med
- 卷：134
- 期：12
- 页码：1385-1396
- 数据来源：sp
摘要
Purpose To assess quality of life (QOL) data from a double-blind Phase III study evaluating bicalutamide (Casodex™) 80 mg as part of maximum androgen blockade (MAB) in patients with previously untreated advanced prostate cancer.